Clairity Secures $43 Million in Funding to Propel AI-Driven Breast Cancer Prediction Platform
Clairity has successfully completed a funding round aggregating $43 million, priming the company for enhanced commercialization of its AI-driven breast cancer prediction platform.
The Series B funding, spearheaded by venture capital firms ACE Global Equity and Santé Ventures, saw participation from existing backer the Breast Cancer Research Foundation (BCRF), alongside a cohort of new investors.
At the forefront of Clairity’s offerings is Clairity Breast, a sophisticated platform designed to quantify a woman’s five-year breast cancer risk by utilizing data derived from routine mammograms.
The company asserts that the platform meticulously analyzes subtle imaging attributes on screening mammograms that correlate with prospective breast cancer risks.
The underlying objective of this platform, which received a de novo classification from the U.S. Food and Drug Administration (FDA) in June 2025, is to transition the paradigm of care from mere detection towards proactive prevention.
With the influx of new capital, Clairity aims to amplify its commercialization strategies for Clairity Breast within the United States.
The initial focus will be on deploying the technology across leading imaging centers and healthcare systems while simultaneously exploring reimbursement initiatives to extend its reach into community imaging facilities.
Jeff Luber, CEO of Clairity, remarked, “With FDA authorization secured and commercial partnerships underway, Clairity Breast is poised to redefine global approaches to breast cancer.”
He added, “We are honored to be at the vanguard of a paradigm shift—from detection to prevention—and to provide technology that equips women and their healthcare providers to predict risks, thereby facilitating timely interventions.”
The early detection of breast cancer, the most commonly diagnosed cancer among women globally, markedly enhances the likelihood of effective treatment and survival.
The stage of the disease at the time of diagnosis is profoundly correlated with patient outcomes. As per GlobalData’s analysis, community outreach must be prioritized to elevate awareness among those affected by breast cancer.
Looking to the future, Clairity indicates that a portion of the funding will also be allocated to further develop its pipeline, aiming to introduce new AI-based predictive tools for other significant diseases by leveraging the same deep learning architecture that underpins Clairity Breast.
AI continues to significantly influence the landscape of medical imaging. GlobalData forecasts that the AI healthcare market will attain a valuation of $19 billion by 2027. One notable player in this domain is imaging software developer DeepLook Medical.
In a conversation with Medical Device Network during Life Sciences Baltics 2025 held in Vilnius, Lithuania, DeepLook Medical’s CEO, Marissa Fayer, characterized the application of AI in imaging as “limitless”.
She emphasized that advancements in technology will likely broaden its scope into comprehensive decision-making, interpretation, and longitudinal forecasting.
Source link: Yahoo.com.
